Exercise of Options, PDMR Dealing, Issue of Equity and Total Voting Rights

04 February 2022

Instem plc
("Instem" or the "Company")

Exercise of Options, PDMR Dealing, Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 2 February 2022 that certain Directors of the Company exercised share options (“Share Options”) over, in aggregate, 100,000 ordinary shares of 10 pence each in the Company (“Ordinary Shares”).

Subsequently, on 2 February 2022, certain Directors sold a portion of the Ordinary Shares issued on the exercise of the Share Options to finance the cost of exercise (where applicable) and associated tax liabilities.

Details of the Directors who participated in the exercise of Share Options and subsequent sale of Ordinary Shares are as follows:

Number of: Exercise price per Ordinary Share Resultant interest in Ordinary Shares Resultant interest in Ordinary Shares (%)
Name of Director Share Options exercised Ordinary Shares sold
Phil Reason 80,000a 40,000 Nil 770,714 3.46%
Nigel Goldsmith 20,000b 12,500 176p 10,000 0.04%

a In relation to options granted on 22 February 2018 and exercisable on or before 15 March 2022
b In relation to options granted on 7 February 2012 and exercisable on or before 7 February 2022

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 100,000 new Ordinary Shares to trading on AIM (“New Ordinary Shares”). Admission is expected to take place at 8.00 a.m. on 9 February 2022.  

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,289,856 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,289,856.

The figure of 22,289,856 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Instem plc Via Walbrook
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel  
Alex Bond  
Rachel Hayes  
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0)20 7710 7600
Ben Maddison  
Alex Price  
Wallbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome  

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit instem.com.